miR-200通过靶向PD-L1抑制非小细胞肺癌A549细胞增殖、迁移和侵袭的研究

目的探讨miR-200对非小细胞肺癌A549细胞的增殖、迁移和侵袭的影响及其与程序性死亡受体配体-1(Programmed death-ligand 1,PD-L1)的靶向关系。方法选取非小细胞肺癌细胞株A549,正常肺成纤维细胞HLF-1为研究对象,根据A549细胞转染物质的不同,分为NC组(未进行任何处理的A549细胞)、miR-NC组(转染miR-NC)、miR-200组(转染miR-200-mimic)、si-NC组(转染si-NC)、si-PD-L1组(转染si-PD-L1)、miR-200+pEGFP组(转染miR-200-mimic+pEGFP)及miR-200+pEGFP-PD-L1组(转染miR-200-mimic+pEGFP-PD-L1)。采用实时荧光定量PCR法检测细胞中miR-200表达水平;MTT检测细胞增殖能力;Transwell小室实验检测细胞迁移、侵袭能力;Western blot检测细胞PD-L1表达水平;荧光素酶实验验证miR-200与PD-L1的靶向关系。结果与HLF-1相比,A549细胞胞miR-200表达水平降低,PD-L1基因、蛋白表达升高(P0.05)。48和72 h时,miR-200组细胞活力、迁移和侵袭数量明显低于NC组、miR-NC组(P0.05)。48和72 h时,si-PD-L1组细胞活力、迁移和侵袭数量明显低于NC组、si-NC组(P0.05)。miR-200+pcDNA-PD-L1组细胞48、72 h时细胞活力、细胞迁移和侵袭数量高于miR-200+pcDNA组、miR-200组(P0.05)。与对照组相比,A549细胞PD-L1野生型质粒组荧光素酶活性明显降低(P0.05),PD-L1突变型质粒组荧光素酶活性无明显变化(P0.05)。结论 miR-200可负性调控PD-L1抑制非小细胞肺癌A549细胞增殖、迁移和侵袭。     

miR-34a逆转非小细胞肺癌A549/DDP细胞对顺铂的耐药性及其机制

目的探讨过表达miR-34a对非小细胞肺癌A549/DDP细胞顺铂(DDP)耐药性的影响及可能机制。方法成功构建过表达miR-34a的真核载体p CDNA3.1+miR-34a后,将A549/DDP细胞分为对照组(无转染)、空转染组(转染空质粒)和过表达组(转染p CDNA3.1+miR-34a),采用实时荧光定量PCR(q PCR)法检测转染24、48、72及96 h后各组miR-34a水平;给予不同浓度DDP(2、4、8、16、32和64μg/ml)处理48 h后采用CCK-8法比较各组对DDP的敏感性,流式细胞仪PI/Annexin V双染法检测各组转染48、96 h后的凋亡率,分别采用Western印迹检测各组转染48、96 h后常见耐药基因的表达情况。结果 A549/DDP细胞的miR-34a水平均低于其亲本细胞A549和正常支气管上皮细胞系HBE(P0.05);与其余两组相比,过表达组转染后的miR-34a水平升高,且对A549/DDP细胞的增殖抑制率升高(P0.05);过表达组的半数抑制浓度均低于其余两组,过表达组转染48、96 h后的凋亡率高于其余两组,而转染48 h后的P-糖蛋白、多药耐药相关蛋白1及肺耐药相关蛋白的水平低于其余两组(P0.05);对照组和空转染组以上指标的差异均无统计学意义(P0.05)。结论 A549/DDP细胞中miR-34a水平较低,通过真核载体将其过表达后可抑制增殖率并提高其对DDP的敏感性,可能与其诱导凋亡及降低耐药基因的表达有关。     

miR-605-3p/TRIB3/β-catenin信号通路调控肺癌的发展

目的探讨miR-605-3p是否影响肺癌细胞A549的增殖和细胞活力。方法转染合成的miR-605-3p模拟物过表达miR-605-3p为过表达组,转染合成的miR-605-3p抑制剂敲低miR-605-3p为敲低组,通过CCK-8和MTT检测2组肺癌细胞A549的增殖水平和细胞活力。通过miRDB在线分析miR-605-3p潜在底物,并通过荧光素酶报告实验验证并分析潜在底物的作用。结果过表达组肺癌细胞A549的增殖水平和细胞活力较对照组均下降(t=12.45、15.38,P值均<0.05);敲低组肺癌细胞A549的增殖水平和细胞活力较对照组均上升(t=11.54、8.45,P值均<0.05)。miR-605-3p靶向TRIB3的3′端非编码区(t=17.32,P值均<0.05)。过表达TRIB3后,肺癌细胞A549的增殖水平和细胞活力均上升(t=10.45、9.04,P值均<0.05)。敲低TRIB3后,肺癌细胞A549的增殖水平和细胞活力均下降(t=8.43、17.43,P值均<0.05)。过表达miR-605-3p后,TRIB3的表达下降,β-catenin进入细胞核的量减少;敲低miR-605-3p后,TRIB3的表达上升,β-catenin进入细胞核的量增加。同时敲低miR-605-3p和TRIB3或miR-605-3p和β-catenin,发现肺癌细胞A549的增殖水平和细胞活力差异无统计学意义(t=0.42、0.61,P值均>0.05);过表达TRIB3的同时敲低β-catenin,发现肺癌细胞A549的增殖水平和细胞活力差异无统计学意义(t=0.56、0.21,P值均>0.05)。结论miR-605-3p靶向TRIB3抑制β-catenin的入核水平,抑制肺癌细胞A549的增殖水平和细胞活力。     

Frat1通过Wnt/β-catenin信号通路对非小细胞肺癌A549细胞增殖、凋亡的影响

目的探讨Frat1能否通过Wnt/β-catenin信号通路对非小细胞肺癌A549细胞的增殖、凋亡产生影响。方法 RT-PCR检测非小细胞肺癌组织及正常肺组织中Frat1、β-catenin的表达;CCK-8试验检测Frat1沉默组和Frat1正常表达组非小细胞肺癌A549细胞的增殖;TUNEL免疫荧光法检测Frat1沉默组和Frat1正常表达组非小细胞肺癌A549细胞的凋亡;Western Blot检测Frat1沉默组和Frat1正常表达组非小细胞肺癌A549细胞β-catenin蛋白的表达。结果非小细胞肺癌组织中Frat1、β-catenin基因的表达显著高于正常肺组织(P0.05);Frat1沉默组细胞的增殖能力显著弱于Frat1正常表达组(P0.05);Frat1沉默组细胞的凋亡显著高于Frat1正常表达组(P0.05);Frat1正常表达组细胞β-catenin蛋白的表达显著高于Frat1沉默组(P0.05)。结论 Frat1与β-catenin在非小细胞肺癌的表达被激活;Frat1能促进非小细胞肺癌A549细胞的增殖,抑制其凋亡,这种作用可能是通过激活Wnt/β-catenin信号通路而实现的。     

microRNA-223对糖基化终产物诱导人脂肪间充质干细胞凋亡和氧化应激影响的体外研究

目的观察microRNA-223(miR-223)对糖基化终产物(AGE)诱导人脂肪间充质干细胞(h ADSC)凋亡和氧化应激的影响。方法采用酶消化法分离培养h ADSC,并应用流式细胞术对表面抗原CD14、CD34、CD45、CD90、CD105和人类白细胞抗原DR(HLA-DR)进行检测。将h ADSC分为牛血清白蛋白(BSA)对照组、AGE修饰的牛血清白蛋白(AGE-BSA)作用组、miR-223模拟物转染组、miR-223模拟物转染+AGE-BSA组、miR-223抑制物转染组和miR-223抑制物转染+AGE-BSA组。应用CCK-8法和TUNEL染色检测各组细胞存活率和凋亡率,Western blot检测Cleaved Caspase3蛋白表达水平,应用双氯荧光素(DCFH-DA)试剂盒检测各组细胞活性氧(ROS)含量。结果流式细胞术检测结果表明,原代培养的h ADSC高表达CD14、CD90和CD105,不表达CD34、CD45和HLADR。CCK-8法、TUNEL染色、Western blot和DCFH-DA法检测结果表明,与BSA对照组相比,AGE-BSA作用组h ADSC凋亡率、miR-223表达水平、Cleaved Caspase3蛋白表达水平、ROS生成显著升高,而细胞存活率下降(P0.05);与AGE-BSA作用组相比,miR-223模拟物转染能够进一步上调AGE-BSA引起的h ADSC凋亡率、Cleaved Caspase3蛋白表达水平和ROS生成增加,下调AGE-BSA引起的h ADSC存活率减少(P0.05);与AGE-BSA作用组相比,miR-223抑制物转染能够抑制h ADSC凋亡率、Cleaved Caspase3蛋白表达水平和ROS生成增加,拮抗AGEBSA引起的h ADSC存活率减少(P0.05)。结论 miR-223高表达能够促进AGE-BSA引起的h ADSC细胞凋亡和ROS生成,其可能作为调控h ADSC促进糖尿病创伤愈合的新靶点。     

miR-202调控GLI-2干预肺癌A549细胞的增殖和凋亡

目的探讨miR-202对肺癌A549细胞增殖和凋亡的调控作用及其相关机制。方法培养肺腺癌A549细胞和肺正常上皮BEAS-2B细胞,利用Real time-PCR检测miR-202在上述细胞中的表达水平;合成并将miR-202 minic和miR-NC转染进入A549细胞后,应用MTT检测12、24、48 h时细胞的抑制率,使用流式细胞术检测转染后48 h细胞的凋亡情况,利用western blot检测GLI-2蛋白的表达情况;构建野生型和突变型GLI-2 3'UTR插入p MIR-REPORTTMluciferase vector载体,并将其与pRL-TK质粒共转染进入A549细胞,之后分别将等量的pre-miR-202和miR-NC再转染进入A549细胞,利用双荧光素酶报告基因检测试剂盒检测萤火虫和海肾荧光素酶活性。结果 miR-202在A549细胞中的相对表达量显著低于在BEAS-2B细胞中的表达量(P0.01);miR-202 minic组在12、24、48和72 h的细胞抑制率显著高于对照组和miR-NC组(P0.01);miR-NC组在72 h时细胞抑制率显著高于对照组(P0.01)。此外,miR-202 minic组细胞凋亡率显著高于miR-NC和对照组(P0.01),并且miR-NC组的细胞凋亡率显著高于对照组(P0.01)。荧光素酶报告基因结果说明GLI-2是miR-202的靶基因。miR-202minc转染A549细胞后可显著降低GLI-2蛋白的表达,而miR-NC组与对照组相比较,GLI-2蛋白表达无显著差异。结论 miR-202通过下游靶基因GLI-2调控肺癌A549细胞的增殖和凋亡,其可作为治疗肺癌的潜在靶点。     

MiR-21对肺癌细胞增殖与凋亡的影响

目的探讨miR-21对肺癌细胞增殖与凋亡的影响。方法培养人肺癌细胞HBE、H460、A549和H446,将实验分为miR-21 inhibitor组、miRNA scramble组、空白对照组。荧光定量检测肺癌细胞H460、A549和H446 miR-21的表达;荧光定量PCR检测将miR-21 inhibitor和miRNA scramble转染到培养至对数生长期的人肺癌细胞H460后,对照组不转染的各组细胞的表达量;MTT实验检测转染miR-21 inhibitor后对细胞增殖的影响;流式细胞仪检测转染miR-21 inhibitor后对细胞凋亡的影响;Western印迹检测与凋亡相关蛋白的活性。结果肺癌细胞H460、A549和H446miR-21的表达显著高于正常肺癌细胞HBE(P<0.01),由于肺癌细胞株H460的miR-21表达在3个细胞株中高表达,因此选择肺癌细胞株H460做后续研究;将miR-21 inhibitor组和miRNA scramble组转染到肺癌细胞株H460后,荧光定量PCR显示,miR-21 inhibitor组的miR-21的相对表达量为显著低于空白对照组(P<0.01),miRNA scramble组的相对表达量与空白对照组无差异(P>0.05);MTT结果显示,转染4 d后,miRNA scramble组与空白对照组细胞增殖率无差异(P>0.05),而miR-21 inhibitor组显著低于空白对照组(P<0.05),且随时间延长,细胞增殖率逐渐下降;流式结果显示,与空白对照组和miRNA scramble组比较,miR-21 inhibitor组细胞的凋亡率显著升高(P<0.01);Western印迹显示,miR-21 inhibitor组Cleaved-caspase-3和Bax蛋白的表达显著高于miRNA scramble组和空白对照组,而miR-21 inhibitor组Bcl-2蛋白的表达显著低于miRNA Scramble组和空白对照组(P<0.05)。结论下调miR-21的表达,可抑制肺癌细胞H460的生长,增加细胞的凋亡,其作用机制可能与Bcl-2家族的调节有关。     

miR-196a对非小细胞肺癌A549增殖及上皮间质转化的影响

目的探讨microRNA-196a(mi R-196a)对非小细胞肺癌(NSCLC)A549细胞增殖及上皮间质转化(EMT)的影响。方法通过实时荧光定量PCR(q RT-PCR)检测人NSCLC细胞系A549与正常支气管上皮细胞系HBE中miR-196a的表达水平。根据实验将A549细胞分为对照组、空转染组、mi R-196a抑制(转染inhibitor)组和mi R-196a过表达(转染mimics)组。采用qRT-PCR检测转染24、48、72、96 h各组的转染效果,四甲基偶氮唑蓝比色法(MTT)检测各组转染24、48、72、96 h的增殖能力,Western印迹法检测各组转染48 h后的上皮表型标志物〔角蛋白(CK)18和钙黏蛋白(E-cadherin)〕和间充质表型标志物〔α-平滑肌肌动蛋白(α-SMA)和纤连蛋白(FN)〕的蛋白水平,采用流式细胞仪和酶联免疫吸附法(ELISA)测量各组转染24、48、72、96 h的A549细胞α-SMA阳性率和细胞上清液中FN水平。结果 A549细胞的mi R-196a水平高于HBE细胞(P0.05),且转染mi R-196a inhibitor或mimics可呈时间依赖的方式降低或升高A549细胞的miR-196a水平(P0.05);与对照组相比,mi R-196a抑制组转染24、48、72、96 h的增殖率及α-SMA阳性率和上清液FN水平均降低,转染48 h的CK18和E-cadherin的蛋白水平升高,α-SMA和FN的蛋白水平降低;而mi R-196a过表达组以上指标的变化趋势与mi R-196a抑制组相反,与其余3组均有统计学差异(P0.05)。结论 A549细胞中mi R-196a呈高表达,抑制mi R-196a表达可抑制A549细胞增殖和EMT,而升高mi R-196a表达可促进A549细胞增殖和EMT。     

miR-92a对H9C2心肌细胞增殖、凋亡及Wnt信号通路的影响

目的探讨miR-92a对过氧化氢(H2O2)诱导的H9C2心肌细胞增殖、凋亡及Wnt信号通路的影响。方法通过Lipofectamine~(TM)2000将miR-92a抑制物(inhibitor)及阴性对照组转染大鼠心肌细胞H9C2,RT-PCR检测转染后细胞中miR-92a的表达;将后续实验分为空白对照组、H2O2组和miR-92a inhibitor+H2O2组,利用CCK8法、流式细胞仪及Western印迹分别检测3组细胞的增殖、凋亡、凋亡相关蛋白B细胞淋巴瘤/白血病(Bcl)-2和Bcl-2相关X蛋白(Bax)及Wnt信号通路β-连环蛋白(β-catenin)和c-Myc的蛋白表达。结果 miR-92a inhibitor组miR-92a mRNA表达显著低于空白对照组(P0.05),阴性对照组与空白对照组差异无统计学意义(P0.05);与空白对照组比较,H2O2组细胞增殖显著降低,凋亡率显著增加,Bax、β-catenin、c-Myc蛋白显著上调表达,Bcl-2蛋白显著下调表达(均P0.05),与H_2O_2组比较,miR-92a inhibitor+H_2O_2组细胞增殖显著升高,凋亡率显著降低,Bax、β-catenin、c-Myc蛋白显著下调表达,Bcl-2蛋白显著上调表达(均P0.05)。结论抑制miR-92a的表达可促进H2O2诱导的H9C2心肌细胞增殖,抑制细胞的凋亡,其机制与调节Bax、Bcl-2蛋白及Wnt信号通路表达有关。     

miR-202通过靶向EGFR抑制A549细胞的增殖和侵袭

目的探索miR-202对非小细胞肺癌A549细胞增殖和侵袭的影响及其分子机制。方法实验分为5组,包括miR-NC组,shNC组,miR-202组,shEGFR组和miR-202+EGFR组。五组细胞分别转染miR-NC,sh-NC,miR-202 mimics,shEGFR和miR202+pcDNA3.1-EGFR。采用双荧光酶报告基因法验证miR-202对EGFR的靶向性。实时荧光定量PCR和蛋白免疫印迹法用于检测A549细胞中mRNA和蛋白的表达。采用流式细胞术检测细胞周期。细胞克隆形成和Transwell法用于检测细胞的增殖和侵袭能力。结果双荧光素酶报告基因实验证实miR-202与EGFR的3’-UTR片段结合。miR-202组的miR-202的表达显著高于miR-NC组(P0.05)。转染miR-202 mimics或shEGFR可以显著下调EGFR的mRNA和蛋白表达水平(P0.05),而转染pcDNA3.1-EGFR可以上调因转染miR-202 mimics而下调的EGFR mRNA和蛋白表达水平(P0.05)。过表达miR-202或者敲低EGFR可以使A549的细胞周期停滞在G0/G1期(P0.05),同时抑制A549细胞的增殖和侵袭能力(P0.05)。通过转染pcDNA3.1-EGFR可以逆转过表达miR-202对A549细胞增殖和侵袭的抑制(P0.05)。过表达miR-202通过靶向EGFR显著下调p-PI3K/PI3K,p-AKT/AKT和p-ERK1/2/ERK1/2等蛋白表达的比值(P0.05)。结论 miR-202靶向EGFR抑制PI3K/AKT和MAPK/ERK信号通路,影响A549细胞的增殖和侵袭,可能成为非小细胞肺癌临床治疗的新靶点。     

Pathogenesis of carcinoma of the papilla of Vater

Most adenomas and carcinomas of the small intestine and extrahepatic bile ducts arise in the region of the papilla of Vater. In familial adenomatous polyposis (FAP) it is the main location for carcinomas after proctocolectomy. In many cases symptoms due to stenosis lead to diagnosis at an early tumor stage. In about 80%, curative intended resection is possible. Operability is the most relevant prognostic factor. Most ampullary carcinomas resp. carcinomas of the papilla of Vater develop from adenomatous or flat dysplastic precursor lesions. They can be sited in the ampulloduodenal part of the papilla of Vater, which is lined by intestinal mucosa. They also can develop in deeper parts of the ampulla, which are lined by pancreaticobiliary duct mucosa. Intestinal-type adenocarcinoma and pancreaticobiliary-type adenocarcinoma represent the main histological types of ampullary carcinoma. Furthermore, there exist unusual types and undifferentiated carcinomas. Many carcinomas of intestinal type express the immunohistochemical marker profile of intestinal mucosa (keratin 7?, keratin 20+, MUC2+). Carcinomas of pancreaticobiliary type usually show the immunohistochemical profile of pancreaticobiliary duct mucosa (keratin 7+, keratin 20?, MUC2?). Even poorly differentiated carcinomas, as well as unusual histological types, may conserve the marker profile of the mucosa they developed from. These findings underline the concept of histogenetically different carcinomas of the papilla of Vater which develop either from intestinal- or from pancreaticobiliary-type mucosa of the papilla of Vater. Molecular alterations in ampullary carcinomas are similar to those of colorectal as well as pancreatic carcinomas, although they appear at different frequencies. In future studies, molecular alterations in ampullary carcinomas should be correlated closely with the different histologic tumor types. Consequently, the histologic classification should reflect the histogenesis of ampullary tumors from the two different types of papillary mucosa.     

Demonstration of the mechanism of action of biguanides

Summary Palmitic acid oxidation in rat diaphragm homogenate is depressed by biguanide concentrations that are still incapable of inhibiting oxidative phosphorylation. Glucose oxidation is not directly effected by the same biguanide concentrations: however, the inhibitory effect of palmitic acid on glucose oxidation is partly removed by biguanides. Inhibition of fatty acid oxidation, which accounts for most of the metabolic effects caused by these drugs, can be regarded as the fundamental mechanism of action of biguanides. There is some evidence suggesting that these drugs might interact with carnitine, thus preventing long-chain fatty acids from being transported across the mitochondrial membrane to the site of oxidation. Traduzione a cura degli AA.     

胰岛素瘤的解剖分布特点分析

目的胰岛素瘤是最常见的胰腺神经内分泌肿瘤，因其临床表现多样，导致诊断困难。影像学诊断尤其是超声内镜(EUS)在胰岛素瘤的诊断中起着重要作用，拥有较高的敏感性和特异性。本研究拟通过明确胰岛素瘤的解剖分布特点，以期有助于提高影像学的诊断准确率和降低漏诊率，尤其是在教育和培训实践中对于EUS的学习者更具有指导价值。 方法回顾性分析解放军总医院第一医学中心病案资料数据库1993年1月至2019年11月经外科手术、病理确诊为胰岛素瘤的患者的临床资料，检索方法采取搜索术后病理诊断为"胰岛素瘤"的病例，通过查阅病例的方法，提取出胰岛素瘤的大小和解剖分布等数据，进一步分析其特点。 结果共检索到确诊为胰岛素瘤的患者116例，其中，男45例、女71例，年龄13～76岁，平均年龄(44.4±14.85)岁。胰岛素瘤单发110例(94.8%)、多发6例(5.2%)。位置分布：头颈部46例(39.7%)，单发45例、多发1例；体尾部68例(58.6%)，单发65例、多发3例；全胰腺多发2例(1.7%)。病变大小特点：最大径0.4～3.4 cm，平均大小(1.53±0.58)cm。≤1 cm 29例、>1 cm而≤1.5 cm41例、>1.5 cm而≤2.0 cm28例，≤3 cm 15例，>3 cm 3例。年龄与肿瘤的大小相关，≤44岁患者肿瘤平均大小为(1.36±0.51)cm、>44岁患者肿瘤平均大小为(1.70±0.60)cm，P<0.05。头颈部的肿瘤大于体尾部的肿瘤，头颈部肿瘤平均大小(1.66±0.63)cm，体尾部(1.42±0.52)cm，P<0.05。 结论胰岛素瘤在胰腺体尾部较头颈部更好发；绝大多数单发，但可以全胰腺多发；多数小于1.5 cm，肿瘤的大小与患者年龄和肿瘤的解剖分布相关。     

氯硝柳胺悬浮剂的毒性评价

目的评价氯硝柳胺悬浮剂的毒性，为现场大规模应用灭螺提供依据。方法按照中华人民共和国国家标准GB 15670-1995《农药登记毒理学试验方法》和鱼类毒性试验方法进行。结果经口、经皮肤的LDso雌、雄性大鼠均>5 000 mg/kg，经呼吸道的LCso雌、雄性大鼠均>5 000mg/m3，该药经口、经皮肤、经呼吸道毒性均属微毒类药物；兔眼用药后，观察期内无不良反应，对眼无刺激性；皮肤用药后对皮肤无刺激性。与氯硝柳胺原药、氯硝柳胺乙醇胺盐原药和氯硝柳胺乙醇胺盐可湿性粉剂相比，氯硝柳胺悬浮剂对鱼急性毒性最低。结论氯硝柳胺悬浮剂属微毒类药物，对鱼的毒性低于其乙醇胺盐可湿性粉剂，适合于现场应用。     

Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease

BACKGROUND AND AIM: Both the clinical presentation and the degree of mucosal damage in coeliac disease vary greatly. In view of conflicting information as to whether the mode of presentation correlates with the degree of villous atrophy, we reviewed a large cohort of patients with coeliac disease. PATIENTS AND METHODS: We correlated mode of presentation (classical, diarrhoea predominant or atypical/silent) with histology of duodenal biopsies and examined their trends over time. RESULTS: The cohort consisted of 499 adults, mean age 44.1 years, 68% females. The majority had silent coeliac disease (56%) and total villous atrophy (65%). There was no correlation of mode of presentation with the degree of villous atrophy (p=0.25). Sixty-eight percent of females and 58% of males had a severe villous atrophy (p=0.052). There was a significant trend over time for a greater proportion of patients presenting as atypical/silent coeliac disease and having partial villous atrophy, though the majority still had total villous atrophy. CONCLUSIONS: Among our patients the degree of villous atrophy in duodenal biopsies did not correlate with the mode of presentation, indicating that factors other than the degree of villous atrophy must account for diarrhoea in coeliac disease.     

CagA-Hp抗体IgG与胃炎的组织学分析

研究幽门螺杆菌(Hp)感染与胃炎的关系。方法对204例慢性胃炎患者胃粘膜进行观察分析,并测定其中137例Hp阳性患者血清CagA-Hp抗体IgG水平,与组织学对照。结果慢性萎缩性胃炎伴肠上皮化生患者血清CagA抗体IgG明显高于对照组(P＜0.01);其他类型胃炎患者血清CagA抗体IgG水平无明显增高(P＞0.05)。结论CagA-Hp可能是导致慢性萎缩性胃炎伴肠上皮化生的因素之一,对这类患者应密切随访观察。     

血吸虫童虫生长发育及其机制的研究进展

血吸虫童虫是宿主免疫系统攻击的重要靶标,包括皮肤型、肺型和肝门型童虫。宿主分子对童虫生长发育具有重要作用。童虫生长发育机制包括免疫调节、信号转导、性别发育及凋亡等。肌动蛋白、组织蛋白酶、烯醇化酶和葡萄糖基转移酶等分子为血吸虫童虫生长发育的重要分子。本文对血吸虫童虫生长发育及其机制的研究进展做一综述。     

慢阻肺急性加重期患者预后的影响因素分析

目的探讨慢性阻塞性肺病急性加重期(AECOPD)患者预后的相关危险因素。方法回顾性调查、收集58例AECOPD患者可能影响其预后的相关因素,并对其分别进行单因素分析。并进行Logistic多元逐步回归进行多因素分析,筛选影响AECOPD患者预后的独立危险因素。结果单因素分析后将结果 P0.1的因素纳入多因素Logistic回归,分析发现是否合并呼吸衰竭、气促程度、白细胞计数、APACHEⅡ、应用抗氧化剂、慢阻肺治疗依从性为影响AECOPD患者预后不佳的独立因素(P0.05)。结论根据AECOPD患者预后的独立危险因素,及早判断,选择合适的后续治疗方案,对提高其生存率及生存质量具有重要意义。     

124例耐多药结核分枝杆菌基因突变特征分析

目的对临床分离的耐多药结核分枝杆菌相关基因的突变特征进行分析。方法对124例耐多药结核分枝杆菌以及50株敏感株的耐药相关基因(包括异烟肼inh A、kat G、oxyR-ahp C间隔区以及利福平rpo B)进行序列测定,分析其基因突变情况。结果异烟肼耐药inh A基因突变率为14.5%;kat G基因突变率为70.2%(87/124),主要位于315位;oxyR-ahp C间隔区突变率为15.3%;inh A、kat G两种基因同时突变率75.0%,三种基因同时突变率为89.5%。利福平rpo B基因突变的检出率高达95.2%,突变主要发生在531、526、516位点。结论我省耐多药菌异烟肼耐药相关基因最常见突变为kat G 315、inh A C-T(-15)、axyR-ahp C间隔区(-10)C-T,利福平为rpo B531、526、516。结合MDR-TB耐药相关基因的特征分析,可以建立一种快速、准确、特异的适合于我省的检测结核菌耐多药性的新方法。     

Results of treatment of fistula-in-ano

To evaluate the application of Parks' classification in the management of patients with fistula-in-ano, a study was undertaken to assess the outcome of surgery, especially with respect to the recurrence rate and alteration of continence. A retrospective analysis of 160 consecutive patients who were classified at the time of operation was conducted. The distribution of fistulas was as follows: intersphincteric, 41.9 percent, transsphincteric, 52.1 percent, suprasphincteric, 1.3 percent, extrasphincteric, 0. A horseshoe extension occurred in 8.8 percent of the fistulas and 3.8 percent did not exactly conform to the classification as they were either complex or combinations of more than one type of fistula. The sole immediate postoperative complication was bleeding, which occurred one week postoperatively and ceased spontaneously (0.7 percent). Alteration in continence occurred in 6 percent of patients with 2.6 percent experiencing temporary incontinence to flatus, 1.3 percent to liquid stool, and 0.7 percent to solid stool. Permanent loss of control for flatus occurred in one patient (0.7 percent) and for liquid stool in one patient (0.7 percent). No patients suffered loss of control for solid stool. Recurrence developed in 6.3 percent of patients, all between five and 25 months postoperatively. Classifcation was found to be a useful guide in the operative management of patients with fistula-in-ano. Read at the joint meeting of the American Society of Colon and Rectal Surgeons with the Section of Colo-Proctology, Royal Society of Medicine, and the Section of Colonic and Rectal Surgery, Royal Australasian College of Surgeons, New Orleans, Louisiana, May 6 to 11, 1984.